Medicare lab spending totaled $8.4 billion in 2024, up 5 percent year over year, with $3.6 billion of that spent on genetic testing, an increase of 20 percent over 2023.

PHILADELPHIA--(BUSINESS WIRE)--Vivodyne, a biotech that discovers and develops more effective drugs by testing them on lab-grown human organs, today announced the close of $38 million in total seed ...

In a landmark decision poised to revolutionize drug development, the U.S. Food and Drug Administration (FDA) has announced a new initiative to significantly reduce, refine, and replace animal testing ...

Scientists in Zlín are developing an advanced model of the human small intestine. The main goal behind this effort is to ...

Khosla Ventures-backed Vivodyne is growing human tissues in the lab to test potential new therapies before they go to clinical trials. Only about 10% of drugs in development ever make it to market.

The Food and Drug Administration and National Institutes of Health held a joint workshop July 7 on reducing animal testing in research, strikingly announcing that “NIH will no longer seek proposals ...

Andrei Georgescu, PhD, CEO of Vivodyne, was hoping to couple his interests in science and engineering when he chose UPenn for his graduate research. His goal was to build on his background in ...